A director at Umicore S.A. sold 2,739 shares at 17.990EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
AkzoNobel: 1Q26 beat and FY guidance maintained. ASM International: 1Q26 results, great start to the year. Basic-Fit: Highlights of Capital Markets Day 2026. BE Semiconductor Industries: 1Q26 Preview - building strength. Cofinimmo: Earnings beat, muted investments; Armonea agreement reached. Corbion: Not so sweet. MICC: Peer Danone 1Q26 results. Randstad: Slight beat on 1Q26, trends improving; 2Q26 guidance at least in line. Recticel: 1Q26 in line, sharp pick-up expected in 2Q. ...
Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), April 21, 2026 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 9, 2026 its intention to repurchase ordinary shares with an aggregate market value of €500 million and reduce its issued capital. On March 12, 2026, the company commenced repurchasing ordinary shares for a total amount of €540 million, of which €40 million to co...
UCB announced that it has entered into a definitive agreement to acquire Neurona Therapeutics, including lead epilepsy cell therapy asset NRTX-1001, for a $ 650m upfront and up to $ 500m in potential milestones. We're encouraged by NRTX-1001's phase 1/2 data showing approx. 80% reduction in disabling seizures at 4-6 months post administration in drug-resistant unilateral mesial temporal lobe epilepsy (MTLE), with or without mesial temporal sclerosis (MTS), and look forward to the phase 3 progra...
UCB presented new global, real-world, patient-centric data that highlighted quality of life impacts for epilepsy patients and caregivers at the American Academy of Neurology (AAN) conference, being held 18-22 April. The data shows the impact of sleep disturbances on activities of daily living (ADL) and communication, the negative impact of prolonged seizures on daily activities including work productivity, and the benefit of treatment persistence with Fintepla, which led to reduced healthcare re...
Belfius: strategy 2030 vs FY25 results: acceleration to +5% CAGR. dsm-firmenich: Givaudan 1Q26 trading update. D'Ieteren: Carglass's exclusive mobile ADAS calibration launch in France. EVS: €5m share buy-back programme. SBM Offshore: SEAP & Nigeria. Staffing sector: PageGroup 1Q26 trading update. TomTom: Preview 1Q26, no material changes expected. Zabka: 1Q26 Preview
Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), April 14, 2026 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 9, 2026 its intention to repurchase ordinary shares with an aggregate market value of €500 million and reduce its issued capital. On March 12, 2026, the company commenced repurchasing ordinary shares for a total amount of €540 million, of which €40 million to co...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.